Novo Nordisk A/S
Pfizer, one of the world's largest pharmaceutical companies, has filed a lawsuit against Metsera and Novo Nordisk, Danish biotech company Novo Nordisk, over a bid for Metsera that Novo announced, sparking a high-stakes battle for control of the emerging biotech firm. Metsera is developing potential treatments for obesity
COVID-19
GSK PLC has reached a significant patent settlement with CureVac, valued at $370 million upfront and 1% royalty on US sales of Pfizer and BioNTech's mRNA vaccines. This deal comes after CureVac and BioNTech settled their mRNA patent litigation in the US, with GSK's entitlement stemming
COVID-19
CureVac NV has withdrawn its agreement to settle a patent dispute with Pfizer/BioNTech, involving COVID-19 vaccine technology, with CureVac claiming infringement by Pfizer/BioNTech's Comirnaty vaccine. The withdrawal means the dispute will proceed to trial, potentially leading to a lengthy and costly process. This decision comes after
COVID-19
The US government is canceling around $500 million worth of vaccine development projects using mRNA technology, a decision that has triggered criticism from public health experts and officials. The 22 terminated projects, funded through the Biomedical Advanced Research and Development Authority (Barda), included vaccine efforts for Covid-19, flu, and bird
COVID-19
GSK will receive a significant payment as a result of the resolution of patent litigation between CureVac and BioNTech in the United States. The biopharmaceutical company will receive USD370m upfront, with a portion tied to an amendment reducing royalties GSK owes on potential future mRNA vaccines. Additionally, GSK will collect
COVID-19
Pfizer CentreOne, a leading contract development and manufacturing organization (CDMO), is shifting its focus from a traditional "transactional function" to stronger long-term partnerships with a select group of customers. Jim Donovan, the company's vice president, emphasized the importance of building credibility and growing partnerships beyond single
Pfizer Inc.
UK pharmaceutical company Glaxo's RSV vaccine has been overlooked by the NHS in favor of a cheaper alternative from Pfizer, highlighting a broader issue of the UK's commitment to preventative medicine and domestic pharmaceutical innovation. The decision comes despite the GSK vaccine being 10% more efficacious
Pharmaceutical industry
The specialty pharmaceuticals market is expected to grow significantly over the next five years, driven by the increasing demand for research and development (R&D) and government healthcare expenditure. The market size is expected to grow by USD 331.12 billion from 2022 to 2027, with a compound annual
Pharmaceutical industry
The endocrinology drugs market is expected to experience significant growth over the next five years, driven by the increasing prevalence of endocrine disorders such as diabetes. The market is segmented by distribution channel, therapy area, and geography, with North America contributing 45% to the growth of the global market. The
Vaccines
Researchers from the University of Michigan have investigated the effectiveness of three COVID-19 vaccines in individuals on immunosuppressants for various conditions. Their study, published in the Annals of the Rheumatic Diseases, highlights the importance of booster doses for individuals on immunosuppressants. Key Takeaways: * The study analyzed data from 97,688
Vaccines
The Food and Drug Administration has authorized an additional dose of the Pfizer or Moderna vaccine for Americans 50 and older, as well as certain younger people with severely weakened immune systems. This decision expands the eligibility for a booster shot to millions more Americans, especially those with chronic illnesses
Vaccines
The global travel vaccines market experienced significant growth in 2021, reaching a value of $3.2 billion. According to a new report by ResearchAndMarkets.com, the market is expected to witness a compound annual growth rate (CAGR) of 11.1% during the forecast period 2022-2027, driven by increasing international travel,
